جستجوی استاد راهنمای دانشگاهی

Virginia W. Cornish is the Helena Rubinstein Professor in the Departments of Chemistry and Systems Biology at Columbia University. She is a pioneer in synthetic biology, focusing on engineering yeast for diagnostic and therapeutic applications. Her research integrates chemical synthesis and genetic tools to expand cellular capabilities, including yeast biosensors and protein engineering. Education: B.A. in Biochemistry, Columbia University (1991) Ph.D. in Chemistry, University of California, Berkeley (1996) Postdoctoral Fellow, MIT (1996–1999) Research Interests: Her work spans synthetic biology, directed evolution, and live-cell imaging. Key areas include: Development of yeast biosensors for pathogen detection Engineering yeast communities for therapeutic applications Expanding the genetic code for noncanonical amino acid incorporation Chemical tagging for protein visualization and manipulation Recent Article Trends: Recent work emphasizes yeast-based biosensors for clinical diagnostics, scalable peptide-GPCR communication systems, and advances in fluorescent tagging for multiplex imaging. Her group also explores genetic code expansion to study protein dynamics and function. Awards: NSF Career Award (2000) Sloan Fellowship (2003) Protein Society Sigal Award (2009) ACS Pfizer Enzyme Chemistry Award (2009) HHMI Gilliam Adviser (2021) Advising & Grants: She advises a dynamic lab of ~20 students/postdocs. Active grants include NIH, NSF, and DARPA funding for synthetic biology and therapeutics. Her team collaborates on projects like vaccine development and metabolic engineering. Labs & Teams: Her lab at Columbia focuses on translational synthetic biology, with facilities for genetic engineering, imaging, and bioassays. Collaborations include projects on yeast-based diagnostics and protein engineering with groups at Harvard, MIT, and Memorial Sloan Kettering.

• Synthetic Biology
• Protein Engineering
• Chemical Biology
• +۵ مورد دیگر

Andrew L. Goodman, PhD, is the C.N.H. Long Professor and Chair of the Department of Microbial Pathogenesis at Yale School of Medicine. He is also Director of the Yale Microbial Sciences Institute. His research focuses on understanding how gut microbes influence human health, particularly in drug metabolism, host-pathogen interactions, and microbiome ecology. Goodman earned his BA in Ecology and Evolutionary Biology from Princeton University, his PhD in Microbiology from Harvard University, and completed postdoctoral training at Washington University. His lab develops innovative tools such as transposon insertion sequencing (INSeq) and personalized microbiota culture collections. Key contributions include discovering microbiome-driven drug metabolism pathways, mechanisms of bacterial resilience during infection, and bacterial competition strategies. His work has been recognized with awards including the NIH Director’s New Innovator Award and the Presidential Early Career Award in Science and Engineering. Recent research highlights include studies on GPCR-targeted drug modulation by gut microbes (2025), protein-folding mechanisms in bacterial competition (2025), and microbiome responses to time-restricted feeding (2023). Goodman collaborates with institutions like the Diabetes Research Center and Yale Cancer Center, advancing translational microbiome research. Awards: ASPET John J. Abel Award, HHMI Faculty Scholar, Pew Foundation Labs/Teams: Goodman Lab, Yale Microbial Sciences Institute Grants: NIH, Burroughs Wellcome Foundation, HHMI

• Microbial Pathogenesis
• Gut Microbiome
• Drug Metabolism
• +۳ مورد دیگر

Craig Morrell is a Professor at the University of Rochester School of Medicine and Dentistry , with joint appointments in the Departments of Medicine , Microbiology and Immunology , and Pathology and Laboratory Medicine . He serves as Associate Director of the Aab Cardiovascular Research Institute . Education: Sc.B. in Biology, Brown University (1995) D.V.M. , Tufts University School of Veterinary Medicine (2000) Ph.D. in Pathobiology, Johns Hopkins University (2005) His research examines the interface between platelets, vascular biology, and immune cells , focusing on platelet roles in thrombosis, inflammation, and immune regulation. Using advanced mouse models , his lab investigates platelet-derived mediators like β2M and PF4 in diseases such as malaria, stroke, and myocardial infarction. Article trends highlight platelets' dual roles in thrombosis and immune modulation , with recurring themes in vascular inflammation , ERK5 signaling , and age-related immune dysfunction . Scientific Awards: Kenneth M. Brinkous Young Investigators Prize (2008) Deans Gift research award (2006) Multiple travel scholarships and fellowships (2003-2005) Pathology Award-Excellence in Pathology (2000) Mentoring and Teaching : He has mentored 8 doctoral students , 7 undergraduates , and 6 postdoctoral fellows , with a focus on diversity. He serves on thesis committees and the URMC MSTP (MD/PhD) admissions committee . Labs and Collaborations : Leads the Morrell Lab at the Aab Cardiovascular Research Institute, collaborating with institutions like Johns Hopkins and Medical College of Wisconsin.

• Platelet Biology
• Vascular Inflammation
• Thrombosis
• +۵ مورد دیگر

Prof. Iwan de Esch is a Full Professor in the Department of Chemistry and Pharmaceutical Sciences at VU University Amsterdam, leading the Drug Design & Synthesis division and serving as Head of Department. He holds dual appointments in the Faculty of Science and AIMMS (Amsterdam Institute for Molecular and Life Sciences). His research focuses on understanding molecular interactions for drug discovery, employing CADD and FBDD approaches. He co-founded three biotech companies (De Novo Pharmaceuticals, IOTA Pharmaceuticals, Griffin Discoveries) and coordinates the EU-funded FRAGNET network. PhD from VU University (1998) Postdoc at University of Cambridge (Drug Design Group) Recipient of the 2011 Galenus Research Prize Received grants from EU-FP7, IMI, and Dutch STW Research interests span fragment-based drug design, receptor-ligand interactions, and pre-clinical drug candidate development. His work impacts GPCRs, PDEs, kinases, and protein-protein interactions. He teaches courses on drug discovery methodologies and computational tools. Over 200 peer-reviewed publications and 8 datasets/software contributions highlight his impactful career.

• Drug Design
• Fragment-Based Drug Design (FBDD)
• Computer-Aided Drug Design (CADD)
• +۵ مورد دیگر

Bernadette Byrne is a Professor and Associate Dean (Equality, Diversity and Inclusion) at the Faculty of Natural Sciences, Imperial College London, within the Department of Life Sciences. She leads research on membrane protein structure and function, focusing on transporters, receptors, and advanced vibrational spectroscopy techniques for antibody behavior analysis in collaboration with Prof. Sergei Kazarian. Her work is funded by BBSRC, EPSRC, MRC, and EU programs. Affiliations include the Agri Futures Lab, Bacterial Pathogenesis Group, Centre for Structural Biology, and Industrial Biotechnology Hub. She has served as an external examiner at the University of Cambridge and University of Edinburgh, and chairs the BBSRC Committee D. Research interests span membrane biology, biochemistry, structural biology, and biophysics. Recent studies emphasize detergent engineering for protein stabilization and industrial bioprocessing challenges. Her publications highlight innovations in membrane mimetic systems, GPCR signaling, and protein aggregation analysis. She actively contributes to interdisciplinary initiatives such as the Chemical Biology CDT and the Membrane Receptor Network.

• Membrane Biology
• Biochemistry
• Structural Biology
• +۵ مورد دیگر

Surl-Hee Ahn is an Assistant Professor in the Department of Chemical Engineering at the University of California, Davis. Her research focuses on using molecular dynamics (MD) simulations and enhanced sampling methods like the weighted ensemble (WE) to study biological systems, including proteins, nanocrystals, and drug discovery for tuberculosis and other diseases. She leads the Ahn Lab, which develops cutting-edge computational tools, such as ParGaMD and DeepWEST, to advance kinetic and thermodynamic sampling in simulations. Education: Ph.D. in Chemistry (Chemical Physics), Stanford University M.S. in Chemistry, University of Pennsylvania M.A. in Mathematics, University of Pennsylvania B.A. in Biochemistry and Mathematics, University of Pennsylvania (Magna Cum Laude, Vagelos Scholar) Research Interests: Molecular dynamics simulations, enhanced sampling methods, computational drug discovery, vaccine design, protein interactions, and nanomaterial dynamics. Her work bridges computational biology, materials science, and pharmacology, with applications to infectious diseases and neurodegenerative disorders. Awards and Recognition: 2020 ACM Gordon Bell Prize Winner (SC20) for SARS-CoV-2 spike dynamics simulations 2021 Chancellor’s Outstanding Postdoctoral Scholar Award Finalist MIT Rising Stars in Mechanical Engineering (2018) ACS PHYS Division Young Investigator Award (2021) Grants & Collaborations: Her research is supported by grants from SC20/SC21 and leverages high-performance computing for multiscale modeling. She collaborates on projects like #COVIDisAirborne, combining AI with computational microscopy. Labs & Teams: The Ahn Lab at UC Davis emphasizes interdisciplinary training in computational methods and their application to real-world biomedical challenges.

• Molecular Dynamics Simulations
• Enhanced Sampling Methods
• Drug Discovery
• +۷ مورد دیگر

Professor Graham Ladds is a Professor of Receptor Pharmacology at the University of Cambridge's Department of Pharmacology and Fellow of St John's College. He serves as Co-Director of the Cambridge Academy of Therapeutic Science and Director of Studies for Pharmacology. His academic journey includes a BSc in Biochemistry from the University of Birmingham and PhD in yeast pheromone signalling from the University of Warwick, where he progressed to Associate Professor before joining Cambridge in 2015. His research focuses on G protein-coupled receptor (GPCR) pharmacology, specializing in: Agonist bias mechanisms and signaling dynamics Mathematical modeling of receptor-ligand interactions RAMPs (Receptor Activity-Modifying Proteins) in Class B1 GPCRs Intracellular calcium signaling pathways Development of biosensors for receptor activity screening He employs multidisciplinary approaches combining pharmacological assays, computational modeling, and machine learning. His recent publications demonstrate strong focus on adenosine receptor pharmacology, GPCR signaling bias, and therapeutic applications for metabolic/cardiovascular disorders. Research frequently appears in high-impact journals with significant industry collaboration themes. Honors include: Fellow of the British Pharmacological Society (2020) Royal Society Industry Fellowship for collaboration with AstraZeneca He leads a 17-member research group investigating GPCR signaling dynamics and maintains active industry partnerships with GSK, Takeda, and AstraZeneca. His teaching includes lectures on drug-receptor interactions and diabetes therapeutics for medical/natural sciences students. Laboratory activities focus on: BRET-based molecular probing of GPCR interactions Development of computational models for receptor activation Calcium signaling studies continuing legacy of Professor Colin Taylor Industry-linked drug discovery projects

• Pharmacology
• G protein-coupled receptors
• Signal Bias
• +۵ مورد دیگر

Jens Carlsson is a Professor at Uppsala University, affiliated with the Department of Cell and Molecular Biology and the Science for Life Laboratory (SciLifeLab) . His research focuses on computational biochemistry , particularly G protein-coupled receptors (GPCRs) , using physics-based modeling to advance structure-based drug design . Academic rank: Full Professor (since 2022) Key methodologies: Molecular dynamics simulations, docking, free energy calculations Research themes: GPCR ligand interactions, virtual chemical space screening, allosteric modulators Recent work (2025) highlights AI-driven discovery of brain disease therapeutics and DNA repair inhibitors , while 2024 projects explore AlphaFold applications in TAAR1 agonist design . His group has received Swedish Research Council grants (3.6M SEK, 6M SEK) and industry collaborations . Scientific awards include the Göran Gustafsson Prize (2016), Excellence Prize in Molecular Design (2022), and Ingvar Carlsson Award (2012). Key students include PhD candidates Mariama Jaiteh and Pierre Matricon , with postdocs like Nicolas Panel and Duy Duc Vo .

• G protein-coupled receptors (GPCRs)
• Structure-based drug design
• Molecular docking
• +۷ مورد دیگر

Dr. Noriko Daneshtalab is an Associate Professor and Associate Dean of Graduate Studies and Research at Memorial University of Newfoundland, with a cross-appointment in the Faculty of Medicine. She is affiliated with the Department of Pharmacy and leads research in cerebrovascular dysfunction, stroke, and pharmacokinetics in inflammatory diseases. Education: B.Sc. in Pharmacology, University of Alberta (1998) Ph.D. in Pharmaceutical Sciences, University of Alberta (2005) Post-doctoral Fellowship, John P. Robarts Research Institute, London, Ontario (2004–2006) – Cell Biology Post-doctoral Fellowship, Memorial University of Newfoundland (2007–2010) – Cardiovascular Research Her research focuses on the mechanisms of cerebrovascular dysfunction associated with chronic inflammation, particularly in autoimmune diseases, and how this predisposes individuals to stroke. She investigates the pharmacokinetic and pharmacodynamic alterations of cardiovascular and immunomodulatory drugs in stroke development, especially in the context of arthritis models. Her work also explores the role of pro-inflammatory mediators like IL-17a in therapeutic failure of cardiovascular treatments and how disease severity and antihypertensive therapy affect cardiovascular outcomes in rheumatoid arthritis (RA) patients. The recent publications highlight her focus on cerebrovascular regulation in stroke-prone models, antihypertensive drug effects on cerebral blood flow, and novel biomaterials for drug delivery. These works span neuroscience, cardiovascular pharmacology, and pharmaceutical technology, emphasizing translational research from molecular mechanisms to therapeutic applications. Scientific Awards: Ignite Research Development Corporation (RDC) Fund Dr. Daneshtalab supervises graduate students and leads several research projects, including the development of a hypertensive-arthritic animal model and investigations into IL-17a signaling in cerebrovascular impairment. She has secured research funding, including the Ignite RDC grant, supporting innovation in her field. As Associate Dean, she plays a key role in advancing graduate research and scholarly development within the university. Her current projects are centered in experimental pharmacology and involve molecular signaling, animal modeling, and drug therapy evaluation, contributing significantly to understanding stroke in complex disease states.

• Cerebrovascular Dysfunction
• Stroke Pathophysiology
• Chronic Inflammation
• +۱۲ مورد دیگر

Mahmoud Moradi is a Professor of Physical Chemistry at the University of Arkansas, holding the distinguished position of Bruker Analytical Science Professor in the Department of Chemistry & Biochemistry within the College of Arts & Sciences. With a strong background in physics and computational chemistry, he leads the Biomolecular Simulations Lab (BioSimLab) focusing on protein dynamics and membrane transport mechanisms. Education: Ph.D. in Physics from North Carolina State University M.Sc. in Physics from Sharif University of Technology, Iran B.Sc. in Physics from Sharif University of Technology, Iran Postdoctoral Associate at Beckman Institute and Department of Biochemistry, University of Illinois at Urbana-Champaign (2011-2015) Professor Moradi's research centers around two inter-related questions: (i) how do proteins function by changing their conformation and undergoing concerted motions? and (ii) how can we simulate these functionally important conformational changes at an atomic level? His lab develops and employs Molecular Dynamics (MD) based enhanced sampling techniques to tackle both problems. They are particularly interested in the study of large-scale conformational changes of proteins such as those involved in membrane transport and signal transduction. A novel combination of nonequilibrium and equilibrium MD based techniques are employed to reconstruct the slow biomolecular processes such as inward- to outward-facing structural transition of membrane transporters at an atomic level. This research has implications for understanding disease mechanisms at a molecular level and improving computational methodologies for biomedically relevant applications. Professor Moradi's recent publications demonstrate a strong focus on membrane protein dynamics, particularly examining cholesterol-protein interactions, GPCR mechanisms, and membrane transporter functions. His work increasingly integrates experimental and computational approaches, with a notable emphasis on SARS-CoV-2 spike protein dynamics during the pandemic years. The publications consistently apply advanced molecular dynamics techniques to investigate protein conformational changes, with growing applications in drug delivery systems and computational drug design. Scientific Awards: NIH MIRA (R35) Award, 2022-2027 (as PI): Physics-based characterization of functionally relevant protein conformational dynamics NSF I-Corps Award, 2021-2022 (as PI): Physics-Based Binding Affinity Estimator NSF CAREER Award, 2020-2025 (as PI): Riemannian Reformulation of Collective Variable Based Free Energy Calculation Methods NIH R15 Grant, 2020-2023 (as PI): Molecular Characterization of the Influenza Hemagglutinin Mediated Membrane Fusion DOE Grant, 2020-2023 (as co-PI): Protein Targeting to the Chloroplast Thylakoid Membrane NSF HDR Grant, 2019-2022 (as PI): Atomic Level Structural Dynamics in Catalysts Connor Endowed Faculty Fellowship, 2018 Fulbright College Outstanding Researcher Award for 2023/24 academic year Professor Moradi has successfully mentored numerous graduate students through their PhD programs, with recent graduates including Ehsaneh Khodadadi, Shadi Badiee, and Ugochi Isu. His research is supported by substantial grants from NIH, NSF, and DOE, totaling millions of dollars in funding. His NIH MIRA award represents a significant long-term commitment to his research program, while his NSF CAREER award recognizes both research excellence and educational contributions. The Biomolecular Simulations Lab at the University of Arkansas is a vibrant research group that combines computational and experimental approaches to study protein dynamics, maintaining strong collaborations with experimental groups both within the university and at other institutions.

• Biomolecular Simulations
• Molecular Dynamics
• Protein Conformational Dynamics
• +۵ مورد دیگر

Michael Brown is a Professor of Chemistry and Physics at the University of Arizona, holding a joint faculty appointment. His research focuses on atomic, molecular, and optical physics, biological physics, and nuclear physics. He holds a Ph.D. from the University of California at Santa Cruz (1975). His work explores membrane protein dynamics, lipid interactions, and the role of hydration in G-protein-coupled receptor (GPCR) activation. He employs advanced techniques like solid-state NMR, femtosecond X-ray scattering, and quantum mechanical/molecular modeling. Education: Ph.D., 1975, University of California at Santa Cruz Research interests emphasize understanding how lipid membranes, cholesterol, and water modulate protein function. Key areas include rhodopsin activation mechanisms, antimicrobial peptide interactions, and membrane stiffening effects of cholesterol. His interdisciplinary work bridges computational simulations and experimental techniques. Recent articles highlight studies on lipid-protein interactions, rhodopsin activation dynamics, and membrane mechanics, showcasing his focus on ultrafast biophysical processes and structural biology. Awards: None explicitly stated in provided texts. Advising and grants: No student advisees or grant details listed. Collaborations are central to his research, as seen in joint projects on lipid membranes and GPCRs.

• Atomic, Molecular, and Optical Physics
• Biological Physics
• Nuclear Physics

Erik C. Johnson is Professor and Chair of the Department of Biology at Wake Forest University, College of Arts and Sciences. He holds a Ph.D. and B.A. from the University of Maine and leads a research program focused on neurobiology, molecular signaling, and physiology in Drosophila melanogaster . His work bridges molecular mechanisms with organismal behavior and metabolic regulation. B.A., University of Maine, 1992 Ph.D., University of Maine, 2000 Dr. Johnson's research centers on the neural control of physiology and behavior, with emphasis on neurotransmitter and neuropeptide signaling, biological oscillators, and stress responses. He investigates how G-protein-coupled receptors (GPCRs) regulate neuronal physiology and shape behaviors through receptor desensitization and signaling dynamics. His lab uses Drosophila due to its powerful genetic tools and relevance to conserved biological mechanisms. The recent publications (2010–2023) reflect a strong focus on metabolic regulation, circadian control, neuroendocrine signaling, and sensory biology. Key themes include adipokinetic hormone signaling, AMPK-mediated energy sensing, TRP channel function, and GPCR dimerization. These studies integrate molecular, cellular, and behavioral approaches to dissect conserved physiological pathways. Dr. Johnson has contributed to major reference works such as Hormones, Brain and Behavior and has published in high-impact journals including Cell , PLoS ONE , Journal of Experimental Biology , and Frontiers in Physiology . While no formal awards are listed, his sustained publication record and leadership role indicate significant scholarly recognition. He has mentored numerous students and collaborators, including J.T. Braco, M.J. Rizzo, C.J. Saunders, and others who appear as co-authors on key studies. His research has been supported by internal and external grants, though specific funding sources are not detailed in the text. His lab continues to explore the intersection of neural signaling, metabolism, and behavior. The research is conducted in a molecular and cellular physiology lab within the Department of Biology, utilizing Drosophila genetics, biochemical assays, and behavioral analyses. The team investigates conserved mechanisms of neuronal signaling with implications for human metabolic and neurological disorders.

• Neurobiology
• Physiology
• Molecular Biology
• +۷ مورد دیگر

Lukas Edward Dow is a Professor of Biochemistry and Biophysics at Weill Cornell Medical College (2025-present) and holds a secondary appointment in Medicine. His research spans genetic and non-genetic resistance mechanisms in KRAS-driven cancers, WNT signaling, and CRISPR-based cancer modeling. Ph.D. and B.Sc. from University of Melbourne Focus on CRC, pancreatic, breast, and prostate cancers Research interests include genetic resistance mechanisms , CRISPR applications , WNT pathway dependencies , and tumor microenvironment dynamics . Key publications reveal trends in mutant-specific therapies , epithelial plasticity , and precision genome editing . Current research projects funded by National Cancer Institute and Department of Defense investigate KRAS allelic imbalance, R-Spondin sensitization, and WNT pathway alterations. External collaborations include scientific advisory roles at Mirimus, Inc. and consulting at Revolution Medicines, Inc. His lab develops genetically engineered mouse models and organoid systems for studying cancer progression, with emphasis on metastasis , drug resistance , and epigenetic adaptations . The work has significant implications for improving cancer therapies through context-dependent targeting .

• Cancer Biology
• Genetics
• Molecular Biology
• +۵ مورد دیگر

Anita L. Zimmerman is a tenured Professor of Molecular Microbiology and Immunology at Brown University’s Warren Alpert Medical School. Since 1987 she has progressed from Assistant to Associate to full Professor, served as Director of the MD/PhD Program (2005–2007), Vice Chair of the Department (2008–2021), and currently directs the Graduate Program in Molecular Pharmacology & Physiology. She also holds the position of Director of Student Welfare in the Therapeutic Sciences Graduate Program. Education PhD, Physiology & Biophysics, University of Miami Miller School of Medicine, 1982 AB, Zoology, University of California, Berkeley, 1978 Research Interests Dr. Zimmerman’s scientific career has centered on the molecular and cellular neurobiology of ion channels . Using patch-clamp electrophysiology, molecular biology, and heterologous expression systems, she has elucidated the mechanisms of cyclic-nucleotide-gated (CNG) channels, TRP channels, and their roles in visual phototransduction , UV-light signaling in melanocytes , and synaptic transmission . Her work has clarified how retinoids modulate CNG channel activity and how mutations in these channels lead to retinal disease. Although she no longer maintains an active wet-lab, she continues to provide critical consultation to ongoing projects at Brown and remains a key mentor in NIH-funded training programs. Scientific Awards & Honors Dean’s Excellence in Teaching Award (multiple years) Graduate School Faculty Award for Advising and Mentoring (2011) Brown Advance Scientific Leadership Award (2009) Salomon Faculty Research Award (1998) Rhode Island Foundation Research Grant (1998) Editorial Board Member, Journal of General Physiology (2006–2017) Council Member, Biophysical Society & Society of General Physiologists Training Grants & Mentorship Dr. Zimmerman co-directs the NIH T32 training grant “Interdisciplinary Training in Pharmacological Sciences” (GM139793, 2021-2026) and previously co-directed its predecessor T32 GM077995. She has mentored numerous MD/PhD and PhD students through the MPP Graduate Program and served as Associate Director and Director of the Brown MD/PhD Program (2000–2007). Laboratory & Team While her independent laboratory is now closed, she collaborates closely with colleagues such as Professor Elena Oancea on NIH-funded projects involving UV phototransduction and ion-channel signaling. She remains an integral part of Brown’s multidisciplinary neuroscience and pharmacology community.

• Ion channel biophysics
• Visual transduction
• Cyclic nucleotide-gated (CNG) channels
• +۵ مورد دیگر

Professor Gerhard Wolber leads the Molecular Drug Design research group at the Institute of Pharmacy , Freie Universitaet Berlin. His work focuses on computational approaches to drug discovery, with expertise in G-protein coupled receptors (GPCRs) , cytochrome P450 enzymes , Toll-like receptors , and viral protease inhibitors . He supervises a team of 13 PhD candidates 3 researchers 2 Master's students engaged in projects ranging from calcium channel blockers to CYP enzyme modulators for cancer therapy. Recent publications highlight his lab's contributions to pan-coronavirus drug discovery, TLR8 antagonism, and calcium channel inhibition. The team employs advanced methodologies including Molecular dynamics simulations Fragment-based de novo design Bayesian neural networks DFT calculations 3D pharmacophore modeling to bridge computational predictions with experimental validation. Notable projects include Virtual screening for TREM2-targeted glioblastoma therapeutics Allosteric communication path analysis via MDPath Immune checkpoint inhibitors for cancer immunotherapy Biased GPCR ligand development demonstrating a multidisciplinary approach to contemporary drug design challenges.

• Computational Drug Design
• G-Protein Coupled Receptors (GPCRs)
• Cytochrome P450 Enzymes
• +۳ مورد دیگر